Chembio Appoints Sharon Klugewicz as Chief Operating Officer

Chembio Appoints Sharon Klugewicz as Chief Operating Officer

MEDFORD, N.Y., May 22, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI), a leader in point-of-care diagnostic tests, announced today the
appointment of Sharon Klugewicz as its Chief Operating Officer, effective May
22, 2013.

In this newly created position, Ms. Klugewicz is responsible for all the
Company's operational activities, working closely with each of the functional
areas of the Company including research and development, manufacturing,
regulatory affairs, and sales and marketing. Ms. Klugewicz joined Chembio in
September 2012 as Vice President of Quality Assurance/Quality Control
("QA/QC") and Technical Operations.

Lawrence Siebert, Chembio's Chief Executive Officer, commented, "Sharon has
made a significant impact on Chembio since joining us in September.With the
increasing number of product development, manufacturing and commercial
opportunities we have and are considering, establishing this position with
Sharon's leadership and depth of experience should strengthen the
infrastructure to ensure that the Company's operational needs are fully
addressed and thereby enable us to achieve our long term goals."

Sharon Klugewicz commented, "I am delighted to be part of the Chembio team,
and excited about the opportunity to build and grow the business to meet the
needs of our customers and shareholders.We have a robust pipeline of
innovative products, and are prepared to deliver these superior point-of-care
rapid testing solutions to the market over the next several years and into the
future".

Before joining Chembio Ms. Klugewicz was with Pall Corporation (NYSE:PLL), a
world leader in filtration, separation and purification technologies, where
her most recent role was Sr. Vice President, Scientific & Laboratory Services
(SLS). In this role, she was responsible for lab operations and scientific
staff management globally. During her more than 20 years of experience since
joining Pall as a molecular biologist, Ms. Klugewicz held a number of
positions in the Pall Life Sciences Division, in Marketing, Product
Management, and Field Technical Services, including Sr. Vice President, Global
Quality Operations.Ms. Klugewicz holds an M.S. in Biochemistry from Adelphi
University and a B.S. in Neurobiology from Stony Brook University.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical
Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests
internationally to government and donor-funded programs directly and through
distributors. Chembio has developed a patented point-of-care test platform
technology, the Dual Path Platform (DPP®) technology, which has significant
advantages over lateral-flow technologies.This technology is providing
Chembio with a significant pipeline of business opportunities for the
development and manufacture of new products based on DPP®. Headquartered in
Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U. S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485. For more
information, visit our website at www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended.Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management.Such
statements, which are estimates only, reflect management's current views, are
based on certain assumptions, and involve risks and uncertainties.Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to Chembio's
ability to obtain additional financing and to obtain regulatory approvals in a
timely manner, as well as the demand for Chembio's products.Chembio
undertakes no obligation to publicly update these forward-looking statements
to reflect events or circumstances that occur after the date hereof or to
reflect any change in Chembio's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events.Factors
that may impact Chembio's success are more fully disclosed in Chembio's most
recent public filings with the U.S. Securities and Exchange Commission.

CONTACT: Chembio Diagnostics
         Susan Norcott
         (631) 924-1135, ext. 125
         snorcott@chembio.com
        
         LHA
         Anne Marie Fields
         (212) 838-3777
         AFields@lhai.com
 
Press spacebar to pause and continue. Press esc to stop.